Cannabis Extracts Reduce Toxic Protein Clumps Linked to Parkinson's Disease

What the researchers found

All four cannabis extracts — regardless of dominant cannabinoid (THC at 69.88%, CBD at 52.64%, or CBN at 47.38% and 58.64%) — reduced intracellular alpha-synuclein inclusions in human H4 cells and increased the number of cells without inclusions. All extracts showed antioxidant activity and increased daughter cell production in yeast models, but did not prevent mitochondrial damage.

Why it matters

Alpha-synuclein protein clumps are a hallmark of Parkinson's disease. Finding that cannabis extracts with very different cannabinoid compositions all reduced these clumps suggests multiple cannabis compounds may be neuroprotective — not just CBD or THC alone.

The numbers in context

4 cannabis extracts tested: THC-rich (69.88%), CBD-rich (52.64%), CBN-rich #1 (47.38%), CBN-rich #2 (58.64%). All reduced intracellular inclusions in H4 cells. All increased inclusion-free cells. All showed antioxidant activity (reduced intracellular oxidation). None prevented mitochondrial damage.

How the study worked

Preclinical study testing four Cannabis sativa extracts with different phytocannabinoid profiles in two cell models: Saccharomyces cerevisiae (yeast) and genetically modified human H4 cells, both expressing alpha-synuclein. Evaluated antioxidant activity, inclusion formation, mitochondrial function, and cell viability.

What this study cannot tell us

Cell models only — far from human disease. Alpha-synuclein overexpression in cells doesn't fully replicate Parkinson's. No animal studies. Cannot determine which specific compounds in the extracts are responsible. Mitochondrial damage wasn't prevented despite other benefits.

How to read the evidence

In vitro cell studies only — interesting but very early-stage evidence that requires extensive animal and human validation.

When this study was published

Published in 2026, contributing to growing interest in cannabinoids for neurodegenerative disease.

The bigger picture

Most cannabis research focuses on individual cannabinoids, but this study suggests whole-plant extracts may have neuroprotective properties regardless of which cannabinoid dominates. This supports the 'entourage effect' hypothesis for neurodegenerative diseases.

Questions still open

• Which specific compounds in cannabis extracts are most neuroprotective? Would these effects translate to animal models of Parkinson's? Could cannabis slow Parkinson's progression in humans?

Common questions

Read the original research

Cannabis sativa extracts reduce inclusion formation in a cell model of alpha-synuclein aggregation.

Fitoterapia, 188, 106968

Citation

de Almeida Cruz, Tamires; de Paulo Osorio, Rodrigo; de Menezes Epifanio, Neide Mara; Merghani, Madiha; Pereira, Marcos Dias; de Almeida Chaves, Douglas Siqueira; Outeiro, Tiago Fleming; Riger, Cristiano Jorge. (2026). Cannabis sativa extracts reduce inclusion formation in a cell model of alpha-synuclein aggregation.. Fitoterapia, 188, 106968. https://doi.org/10.1016/j.fitote.2025.106968

Explore the wider topic

• CBD Oil Quality Guide: How to Avoid Snake Oil
• Anxiety After Quitting Weed: When to Consider Medication
• Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
• Cannabis for Chronic Pain: What the Research Actually Supports
• Cannabis and Epilepsy: The Epidiolex Story and What It Means
• Does CBD Actually Work for Anxiety? What the Evidence Shows
• Does CBD Help with Weed Withdrawal? What Studies Show
• CBD vs THC: The Differences That Actually Matter
• The Proven Medical Benefits of Cannabis: What Research Supports
• Quitting Weed Before Surgery
• Weed and Medications: What Changes When You Quit
• Quitting Weed During Pregnancy: What You Need to Know
• Quitting Weed While Pregnant: What You Need to Know
• Cannabis and Older Adults: Risks Seniors Should Know
• Cannabis and Breastfeeding: THC in Breast Milk
• Cannabis and Parkinson's Disease: Tremor, Sleep, and Quality of Life